Reducing Uveitic Glaucoma: therapeutic judgement is the key

Dr Sanjoy Chowdhury, [1] MS.DO.DNB, Dr Hitesh Patel [2], Dr Pratik Bhosale [3]
[1] Joint Director (Medical & Health Services, SAIL/BGH. 4C/3020 BOKARO STEEL CITY, JHARKHAND_827004
[2,3] DNB Residents, Bokaro General Hospital, Jharkhand, India

Abstract:
Background: Uveitic glaucoma (UG) due to disease and/or therapeutics is an important reason for reduced vision. Different therapeutic regimen employed in uveitis can alter the course of UG. Purpose: Evaluation of prevalence of UG with different commonly used therapy.
Study design: Randomised prospective hospital based study
Study Period: 2007-2012
Methods: Baseline IOP; Field and optic nerve head photographs were recorded. Three groups were randomised: 1.topical steroid 2.Systemic steroid + gr 1, 3.Topical synthetic steroids, cycloplegic and periorbital triamcinolone injection.
Outcome measure: IOP more than 22 mm/4 mm increase from baseline is marker.
Results: 1254 cases of uveitis with 82 cases of uveitic glaucoma were included. Prevalence: 63 per100000, 70% in anterior uveitis. During treatment, UG was maximum (80%) in first group and least (5%) with synthetic steroid combined with periorbital triamcinolone. Multi variate analysis shows synthetic steroid and periorbital triamcinolone has least association with UG. Macular oedema was more in UG which improved with low dose acetazolamide.25% cases had progressive visual field loss.
Conclusion: UG is an underappreciated visual threat in uveitis which can be modulated effectively with newer steroids and low dose acetazolamide.

I. Introduction

Despite its relative rarity, uveitis is the third leading cause of preventable blindness worldwide [1,2]. Glaucoma associated with uveitis is one of the most serious complications of intraocular inflammation and most overlooked reason for visual loss. [3]. Over 2 million people worldwide are thought to have uveitis. Despite significant advances in therapeutics, the prevalence of blindness secondary to uveitis has not been reduced in the past 30 years. In the largest population-based study in the United States, the incidence of uveitis was approximately 3 times that of previous estimates and increased with the increasing age of patients. Women had a higher prevalence of uveitis than men, and the largest differences were in older age groups. Unless interventions improve, about 10% of patients with uveitis will be blinded by it. Epidemiological studies in the United States suggest that this underestimates the risk by as much as 4- to 5-fold. The sight-threatening complications of uveitis include damage to the retina and glaucoma.

Patients with uveitis have an increased risk of developing glaucoma not only because of the Uveitis, but also as a side effect of the use of corticosteroids, the mainstay of treatment. The association between uveitis and glaucoma was first reported by Joseph Beer in 1813 as arthritic iritis followed by glaucoma and blindness. In 1891 Priesley Smith proposed the first modern classification of uveitic glaucoma (UG). Specific types of UG were described by Fuchs in 1906 (heterochromic uveitis) and Posner and Schlossman in 1948 (glaucomatocyclitic crisis). [8]

In India uveitic glaucoma studies are from south India(APEDS)(12) and Arvind eye care system and more recently from Sankara deva nethralaya in North east India. They dealt with epidemiological studies and outcome. Most studies in this field are about safe cataract surgical and glaucoma surgical outcomes.

Introduction of synthetic steroids and different paths of administrations are not devoid of complications and questionable efficacy. On this background we have undertaken this randomised prospective study in 2007-2012.

Aim
To evaluate prevalence of secondary glaucoma (SG) in uveitis with different treatment regimen
II. Methods

A randomised prospective hospital based study was conducted at Bokaro general hospital, a super speciality 910 bedded hospital catering a population of more than 2 million. All the cases of uveitis coming to our hospital during 2007 and 2012 were included in this study. Three categories of patients were enrolled: a) Patients coming directly with uveitis related complaints. B) Chronic cases on follow up, c) cross referrals from other departments like orthopaedics, paediatrics, medicine, dermatology and others. This group also includes patients referred from GPs and general ophthalmologists practicing outside. Thus cohorts fairly represent total cases of uveitis in the district population.

Besides standard eye examination, baseline IOP; Field and optic nerve head photographs were recorded. Three groups were randomised:
1. Topical steroid only
2. Systemic steroid and topical steroids,
3. Topical synthetic steroids, cycloplegic and peri orbital triamcinolone injection.

Uveitic glaucoma is diagnosed when IOP is more than 22 mm of Hg or 4 mm increase from baseline. Corneal sensation was also tested as this is leprosy endemic area and prevalence of herpetic eye disease is high. Fundus photograph was taken in all cases where pupil can be dilated and fluorescein angiography was done when macular oedema or unexplained visual loss is recorded. Visual field testing was done in all cases where pinhole corrected visual acuity is at least 6/18 or above. Statistical analysis was done on online software available.

III. Statistical Analysis

Descriptive statistics (frequencies and proportions for discrete variables) were used to determine patient characteristics and the occurrence of events, such as the need for IOP-lowering surgical procedures. Continuous descriptive statistics (mean, median, standard deviation [SD], and range) were determined for measures of VA in the logarithm of the minimum angle of resolution scale and IOP (mmHg). In addition, Kaplan–Meier analysis was performed to evaluate the time from implantation to surgical intervention for IOP management. The mean change in VA from preoperative to postoperative visits for implant placement was analysed using the paired t test.

IV. Results

Total 1254 cases of uveitis were registered during last five years (2007-2012) with a prevalence of 63 /lakh population. Mean incidence is 200/20lakh/year.

50 cases every year develop chronic uveitis. Male predominance is noticed and males are exclusively seen with comorbid ankylosing spondylitis. M: F -2:1
Mean age 32.6 y, 30% cases are of Juvenile category.

Uveitic Glaucoma (UG)

More than 50% cases had anterior variety with equal distribution of intermediate and posterior uveitis. 10% Cases had pan uveitis.
Mean baseline IOP at diagnosis is 17.4mm whereas 21, 6 mm hg was recorded in herpetic eye disease cases. 70 cases had baseline IOP above 22mm and 12 cases had IOP 4mm above the earlier recorded IOP. These 82 cases were diagnosed as secondary glaucoma (6%), 58 cases had anterior uveitis.
550 cases were treated with topical steroids by different ophthalmologists with occasional cycloplegics. 348 cases were treated with topical and oral steroids and occasional cycloplegic. Last 356 cases were treated with synthetic steroids (difluprednate), atropine and single peri orbital injection of triamcinolone acetate.
4 cases lost vision during treatment and 3 cases developed phthisis bulbi following cataract surgery at a tertiary care hospital.
65 cases of the secondary glaucoma were from first group and all were suffering from anterior uveitis. They need glaucoma medication during uveitis treatment and 16 cases till last follow up (2.6yrs). Posterior synchia on presentation present in 45% cases of this category.
12 cases were from second group and had mixed uveitis. Glaucoma medications had to be prescribed to them during uveitis management and to be continued in 6 cases till last follow-up.
5 cases from the last group had secondary glaucoma which subsided with minimal glaucoma therapy.
Acetazolamide 125mg /d was given in CME cases.

Multi variate analysis has shown following as risk factors of secondary glaucoma in uveitis: anterior variety, comorbidity, non–atropinisation and corticosteroids and delayed diagnosis (referred cases more glaucoma).
V. Discussion

Prevalence is 6% which is less compared to US data; this is probably because our data includes cases over five years. Most studies found UG equally distributed among anterior and posterior uveitis. 70% of UG in our study is associated with anterior uveitis which is also the case in single centre study in US. This can be explained by associated cases of ankylosing spondylitis, herpetic eye disease and juvenile arthritis. Younger age predisposes more to glaucoma.

The treatment of uveitis with corticosteroids results in elevated IOP in up to one-third of patients although corticosteroids have proven to be effective in reducing inflammation, prolonged administration can result in elevated IOP by decreasing aqueous outflow. Secondary ocular hypertension from corticosteroid administration is dependent on the dose, the chemical structure of the corticosteroid compound, the frequency and route of delivery, the duration of treatment, and the patient’s susceptibility to steroid response (“steroid responders”). Clinically, a corticosteroid response usually develops 2 to 6 weeks after initiating therapy, but may occur at any time. It is often difficult to distinguish between the side effects of the corticosteroids and the underlying inflammation. Only about 5% of the normal population demonstrates corticosteroid responsiveness but with impaired conventional outflow seen during intraocular inflammation, the corticosteroid response rate rises significantly. The risk factors of being a steroid responder are primary open-angle glaucoma, familial history of glaucoma, rheumatoid arthritis, extremes of age (children and the elderly), and diabetes. Children are especially susceptible to an IOP increase secondary to steroids. Corticosteroids have been reported to cause biochemical and morphological changes in the trabecular meshwork, increasing resistance to aqueous outflow, and several theories have been proposed to explain this phenomenon, including accumulation of glycosaminoglycan in the trabecular meshwork, inhibition of phagocytosis by trabecular endothelial cells, and inhibition of synthesis of certain prostaglandins.

VI. Conclusion

1 in 167 population has uveitis in Bokaro district, 1 in 8 uveitic patients have secondary glaucoma which more predominant in patients with comorbidity who are not atropinised from beginning. This complication is the cause of visual loss in 1 out of 80 uveitis patients and can be prevented in most instances.

References

Reducing Uveitic Glaucoma: therapeutic...

Table 1: Summary of cohorts showing incidence of uveitic glaucoma with different therapeutic regimens

<table>
<thead>
<tr>
<th>Total</th>
<th>Secondary glaucoma at presentation</th>
<th>Anti-glaucoma therapy during uveitis</th>
<th>Prolonged anti-glaucoma</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Statistical analysis</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1254</td>
<td>82</td>
<td>82</td>
<td>22</td>
<td>65(π550)</td>
<td>12(π348)</td>
<td>5(π356)</td>
<td>P&lt;0.05(1&amp;3)</td>
<td>Least SG in g3</td>
</tr>
</tbody>
</table>

Table 2: Uveitic Glaucoma and comorbidity

<table>
<thead>
<tr>
<th>Secondary glaucoma</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>Ankylosing spondylitis</th>
<th>Herpetic eye disease</th>
<th>Metabolic disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of cases</td>
<td>65</td>
<td>12</td>
<td>5</td>
<td>12</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Prolonged glaucoma</td>
<td>16</td>
<td>6</td>
<td>0</td>
<td>12</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Posterior synechia</td>
<td>28</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Anterior uveitis</td>
<td>48</td>
<td>8</td>
<td>9</td>
<td>6</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

Comorbidity significantly (p<0.05) increases risk of glaucoma